Clinical Trial Update: Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating peri-treatment with an SGLT-2 inhibitor to reduce myocardial infarct size and improve remodeling in acute myocardial infarctio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Myocardial Infarction

Drugs mentioned

• SGLT-2 inhibitor

Snippet

Sponsor: Samsung Medical Center | Conditions: Acute Myocardial Infarction, Heart Failure | Phase 4 | Status: RECRUITING